Omickron
The new crown Omickron mutant strain mutated again WHO issued a warning that BF.7 is spreading worldwide. "In a few weeks, it may become mainstream" Are vaccines and oral drugs for the new crown effective for the BF.7 variant? my country has seen the first case of BF.7 new crown infection in China. How should we deal with the epidemic of BF.7 next?
new variant further evades the epidemic
"Omicron is a comprehensive form of virus evolution." Wang Yuge, a scholar of the U.S. vaccine researcher, , research scholar, and doctor of immunology at the National Institutes of Health, told reporters that BF.7 is essentially an Omicron BA.2 lineage virus. From BA.2 to BA.5 to BF.7, new mutant strains are constantly "inverting", the virus spreads continuously, and the ability to evade epidemics is becoming stronger and stronger.
The epidemic situation of the new coronavirus in the United States. U.S. Centers for Disease Control and Prevention official website Figure
Shaanxi Center for Disease Control and Prevention interprets the BF.7 variant strain
BF.7 variant strain
has stronger infectivity than the existing Omickron variant strain
. It can further evade the immune response induced by BA.5
A study that has not yet been peer-reviewed shows that
BF.7 is the most immune escape mutant strain
The symptoms of this strain after infection include: high fever, persistent cough, physical pain, headache, sore throat, changes in smell and loss of appetite. looks around the world. Recently, the US Centers for Disease Control and Prevention’s new coronavirus data monitoring found that BF.7 has become the third largest mutant strain in the United States with the proportion of new coronavirus detected in a short period of time. In Europe, the proportion of Belgium BF.7 reaches 25%, while Germany, France and Denmark account for about 10%. Focusing on the domestic market, On September 28, Hohhot City saw the first BF.7 local new crown infection case. This is the first time that the BF.7 mutant strain has caused a local epidemic in China. On October 7, the reporter learned from the Hohhot COVID-19 epidemic prevention and control press conference that from 0:00 to 24:00 on October 6, Hohhot, Inner Mongolia, 8 new confirmed cases of new coronavirus pneumonia (including 6 asymptomatic infections and 651 asymptomatic infections). According to reports, the current round of epidemic strain in Hohhot is an evolutionary branch of the Omickron BF.7 variant strain, which has stronger contagiousness, diffusion and escape, and is very likely to cause large-scale transmission. The difficulty of handling and controlling the epidemic has also increased exponentially.
"Patients infected with BA.5 are still at risk of being infected with BF.7." Wang Yuge further explained that BF.7 adds the receptor-binding domain RBD mutation R346T on the basis of BA.4/5, which can further escape the neutralizing antibodies induced by BA.5 infection. Therefore, it is likely to become a popular mutant strain this fall and winter.
new crown vaccine , oral medication is still effective for BF.7
More than experts said that 's current current fight against the new crown is still effective.
"Vaccination is still an effective prevention method." Wang Yuge said that the vaccine works by inducing neutralizing antibodies. If the neutralizing antibody level is very high, although the mutant strain BF.7 has a certain escape, it can still protect the human body, and the vaccine still works.
WHO COVID-19 vaccine priority review expert and deputy director of Jiangsu Provincial Center for Disease Control and Prevention Zhu Fengcai told the People's Daily Health Client reporter that breakthrough infections have always existed, and re-infection with the new coronavirus also exists. At present, the vaccine still has protective effect. Moreover, although has enhanced transmission power, most of them are asymptomatic and mild patients.
is not only a vaccine, but the new coronavirus drug should also be effective against the mutant strain BF.7. Academician of the Chinese Academy of Engineering , and Director of the Institute of Drug Research of the Chinese Academy of Medical Sciences Jiang Jiandong told the People's Daily Health Client reporter, "The main target of the new coronavirus small molecule drug is viral replicase, and at present, no mutations were found in the Omickron target site, so the impact on small molecule drugs should be small. Azvudine is effective for the current epidemic strains, and the real world clinical data we collected."
source: Jinguan News
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-